Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 10/20 | 0.88 |
| ▸ | SRC | P12931 | 9/20 | 0.88 |
| ▸ | LCK | P06239 | 7/20 | 0.73 |
| ▸ | EGFR | P00533 | 3/20 | 0.70 |
| ▸ | FYN | P06241 | 3/20 | 0.70 |
| ▸ | YES1 | P07947 | 3/20 | 0.70 |
| ▸ | LYN | P07948 | 3/20 | 0.70 |
| ▸ | HCK | P08631 | 3/20 | 0.70 |
| ▸ | KIT | P10721 | 3/20 | 0.70 |
| ▸ | BCR | P11274 | 3/20 | 0.70 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.70 |
| ▸ | EPHB6 | O15197 | 2/20 | 0.70 |
| ▸ | CSF1R | P07333 | 2/20 | 0.70 |
| ▸ | RET | P07949 | 2/20 | 0.70 |
| ▸ | BRAF | P15056 | 2/20 | 0.70 |
| ▸ | EPHA1 | P21709 | 2/20 | 0.70 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.70 |
| ▸ | EPHA3 | P29320 | 2/20 | 0.70 |
| ▸ | EPHA8 | P29322 | 2/20 | 0.70 |
| ▸ | EPHB2 | P29323 | 2/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1147163 | 0.94 | ABL1 (1.00) | ABL1SRCLCKEGFRFYN | |
| SCHEMBL29352726 | 0.94 | ABL1 (1.00) | ABL1SRCLCKEGFRFYN | |
| SCHEMBL29618220 | 0.94 | ABL1 (1.00) | ABL1SRCLCKEGFRFYN | |
| Hydrochloric Acid SCHEMBL18825557 | 0.93 | ABL1 (0.98) | ABL1SRCLCKEGFRFYN | |
| SCHEMBL13626293 | 0.89 | ABL1 (0.89) | ABL1SRCLCKEGFRFYN | |
| SCHEMBL20042552 | 0.87 | ABL1 (0.86) | ABL1SRCLCKEGFRFYN | |
| SCHEMBL21340693 | 0.86 | ABL1 (0.80) | ABL1SRCLCKEGFRFYN | |
| SCHEMBL20042547 | 0.86 | ABL1 (0.85) | ABL1SRCLCKEGFRFYN | |
| SCHEMBL28625767 | 0.85 | ABL1 (0.83) | ABL1SRCLCKEGFRFYN | |
| SCHEMBL31634946 | 0.85 | ABL1 (0.84) | ABL1SRCLCKEGFRFYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200325130-A1 | Proteolysis Targeting Chimera Compounds and Methods of Preparing and Using Same | UNIV YALE (US) | 2020-10-15 | — | — | US | disclosed |
| EP-3370715-A1 | PROTEOLYSIS TARGETING CHIMERA COMPOUNDS AND METHODS OF PREPARING AND USING SAME | Yale University (US) | 2018-09-12 | — | — | EP | disclosed |
| WO-2017079267-A1 | PROTEOLYSIS TARGETING CHIMERA COMPOUNDS AND METHODS OF PREPARING AND USING SAME | YALE UNIVERSITY (US) | 2017-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200325130-A1 | Proteolysis Targeting Chimera Compounds and Methods of Preparing and Using Same | NEDD4, MDM2, CBL | ABL1 28/4885SRC 121/4885LCK 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.